Over the past decade, the application of immune checkpoint inhibitors (CPI) against immune checkpoints PD-1/PD-L1 and CTLA-4 have revolutionized cancer treatment, both increasing cancer survival time and leading to complete remission in a significant proportion of patients (1). This evidence concerns the gene CTLA4 and cancer.